Bedrijfsoverzicht
Imunon, Inc. is a clinical-stage biotechnology enterprise dedicated to the development of immunotherapies and vaccines designed to address specific medical challenges. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high degree of scientific specialization and regulatory oversight in product development. As of the latest available data, the entity holds a market capitalization of $11.45M and reports no annual revenue figures, while the employee count is not disclosed in the provided records. These valuation metrics indicate that the company is a small-cap entity operating with limited revenue generation, a common characteristic for biotechnology firms in early clinical stages that prioritize research and development expenditures over immediate profitability. The absence of reported annual revenue and the small market cap suggest that the company's current financial model relies heavily on future product approvals and clinical trial successes rather than existing commercial sales streams.
Financiële gezondheid
The company's financial statements reveal a net income of $-14,495,028 and an EBITDA of $-14,358,786, while revenue figures for the trailing twelve months are not available. The significant disparity between the reported net income and EBITDA, alongside the lack of revenue data, indicates a cost structure dominated by operational expenses and research costs that have resulted in substantial losses without corresponding commercial income. Free cash flow stands at $-8,529,147, reflecting a cash burn rate that consumes the company's liquid assets and limits immediate financial flexibility for external expansion or acquisitions. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that signals the company has not yet achieved positive profitability or scale in its revenue generation. The balance sheet shows a cash position of $8.78M against a debt level of $1.01M, resulting in a debt-to-equity ratio of 14.29, which indicates a highly leveraged capital structure relative to its equity base despite the low absolute debt amount. Current ratio is reported at 2.32, suggesting that the company possesses sufficient short-term assets to cover its short-term liabilities, although the overall liquidity is constrained by the negative cash flow trajectory. Return on Equity is -256.4% and Return on Assets is -83.2%, metrics that reveal management's current inability to generate positive returns on the capital invested by shareholders or utilized in asset operations.
Waarderingsbeoordeling
Trailing P/E ratio is not applicable due to negative earnings, while the forward P/E is listed as -0.93, implying that the market anticipates continued losses or that valuation models based on earnings are currently inapplicable for this biotechnology asset. The price-to-book ratio is 1.21, indicating that the market values the company at a slight premium over its book value, which may reflect intangible assets such as intellectual property and clinical data not fully captured on the balance sheet. Price-to-sales ratio is not available, and the EV/EBITDA stands at -0.26, suggesting that traditional valuation multiples are distorted by the company's negative earnings and cash flow profile. The stock has experienced significant volatility, trading between a 52-week low of $2.52 and a high of $41.22, with the current price position relative to this range indicating a recovery from the yearly low but a substantial distance from the yearly peak. The beta value of 2.12 demonstrates that the stock exhibits more than double the volatility of the broader market, making it a high-risk instrument susceptible to sharp price swings independent of general market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both marked as not available, preventing a direct comparison of earnings growth relative to revenue expansion. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the entity reinvests all available capital and earnings back into its research and development programs rather than distributing income to shareholders. The absence of a dividend policy is typical for clinical-stage biotechnology companies that must retain cash to fund ongoing trials and secure future operational runway. Overall, the growth and income profile is characterized by a complete reliance on future commercialization potential rather than current earnings growth or dividend income, creating a speculative investment scenario where value is contingent on the successful progression of the lead clinical program IMNN-001.